Release Details

CAMBRIDGE, Mass., Sep 15, 2011 (BUSINESS WIRE) --

Idera Pharmaceuticals (Nasdaq: IDRA) today announced that Sudhir Agrawal, D.Phil., Chairman and Chief Executive Officer, is scheduled to present at the UBS 2011 Global Life Sciences Conference in New York City on Wednesday, September 21st at 7:30 am ET. Dr. Agrawal will provide a review of Idera's updated corporate strategy, including its plans with respect to its Toll-like Receptor-targeted development programs and its gene silencing oligonucleotide (GSO) technology.

The live audio webcast of the presentation will be available in the Investor section of Idera's website: www.iderapharma.com. An archived version will also be available on the Company's website after the event for a limited time. Please log in approximately 10 minutes prior to the presentation to ensure a timely connection.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.

SOURCE: Idera Pharmaceuticals

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
E-mail: larcudi@iderapharma.com
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
E-mail: cerdman@macbiocom.com